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Screening and confirmatory testing of cadaver organ donors for
hepatitis C virus infection: A U.S. National Collaborative Study. Hepatitis
C virus (HCV) can be transmitted by organ transplantation. Cadaver
organ donors are screened for HCV infection by testing for antibodies to
HCV (anti.HCV). The prevalence of HCV infection and performance of
anti-HCV tests in detecting HCV infection in organ donors are unknown.
Sera from 3078 cadaver organ donors were tested for anti-HCV by a first
generation enzyme-linked immunosorbent assay (ELISAI). Sera from all
137 ELISA1 positive donors and a random sample of 92 ELISA1 negative
donors were tested for anti-HCV by a second generation ELISA
(ELISA2) and for HCV RNA by the polymerase chain reaction. Organ
bank records were reviewed for risk factors associated with HCV infec-
tion. Follow-up was available on 70 recipients of organs from 42 ELISA2
positive donors. The prevalence of HCV RNA, extrapolated to all 3078
donors, was 2.4%. Liver disease, anti-HCV and HCV RNA were detected
more frequently among recipients of organs from ELISA2 positive donors
with HCV RNA than from ELISA2 positive donors without HCV RNA.
Among donors, the sensitivity and negative predictive value of the
ELISA2 for HCV RNA were 100%. However, despite a specificity of
98.1%, the positive predictive value was only 55.1%. Clinical and labora-
tory characteristics did not distinguish ELISA2 positive donors with and
without HCV RNA. The presence of serum HCV RNA in organ donors
predicts the risk of transmission of HCV infection. Discarding organs from
ELISA2 positive donors would eliminate transmission, but organs from
1.88 percent of donors would be wasted. To reduce waste, it is necessary
to develop confirmatory tests with a higher specificity for HCV RNA than
those that are currently available.
Liver disease due to non-A, non-B hepatitis is an important
cause of morbidity and mortality in renal transplant recipients
[1—3]. We have previously shown that hepatitis C virus (HCV), the
principal cause of non-A, non-B hepatitis, can be transmitted by
organ transplantation [4, 5]. In our study, post-transplantation
liver disease was found in 48% of recipients of organs from
cadaver donors with antibody to HCV (anti-HCV) [41. Based on
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these findings, several organ procurement organizations have
adopted a policy restricting the use of anti-HCV positive donors
to life-saving transplants (heart, liver or lung) [4—61. A similar
policy has been recommended by the U.S. Public Health Service
Inter-Agency Guidelines [7]. However, others have reported a
lower prevalence of liver disease among recipients of organs from
anti-HCV positive donors [8—10]. Because of the conflicting data,
some authors have argued against a moratorium on renal trans-
plantation from organ donors with a positive anti-HCV test until
more information is available regarding the prevalence of viremia
among cadaver organ donors, and the performance of anti-HCV
tests in detecting donors at risk of transmitting the virus [11].
The tests currently used to screen cadaver organ donors detect
antibody to HCV but not HCV itself. Consequently, both false
negative and false positive tests can occur, which would lead to
transmission of HCV infection and wastage of uninfected organs,
respectively. The polymerase chain reaction (PCR) has been used
to detect HCV RNA in the serum of anti-HCV positive organ and
blood donors [5, 6, 12, 131. A positive test is associated with
uniform transmission of infection [5, 6, 12, 13]. However, PCR is
not practical for use in anti-HCV positive cadaver organ donors
[14], and hence, other confirmatory tests are required. Therefore,
we initiated a national collaborative study to examine the preva-
lence of HCV infection among cadaver organ donors, confirm the
effect of viremia on the risk of transmission, determine the
sensitivity and specificity of clinical and laboratory tests in iden-
tifying donors with HCV infection, and evaluate strategies for
screening and confirmatory testing of donors for HCV infection.
Methods
Analysis plan
(1) To determine the prevalence of HCV infection among
cadaver organ donors, we analyzed sera from a sample of anti-
HCV positive and anti-HCV negative donors for HCV RNA by
PCR. In this analysis, donors were initially classified by the results
of a first generation enzyme-linked immunosorbent assay
(ELISA1) because it was commercially available at the time of
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New England Organ Bank, 1986—92 1012 2.9% 2.4% 1.7%
MA
Regional Organ Bank of 1987—91 596 6.0% 3.2% 2.7%
Illinois, IL
Lifelink mc, FL 1985—91 521 7.7% 7.3% 4.0%
Center for Organ Recovery 1986—90 516 5.8% 5.4% 2.1%
and Education, PA
Midwest Organ Bank, KS 1988—90 172 4.7% 4.1% 2.0%
Louisiana Organ 1990—91 129 2.3% 2.3% 0.8%
Procurement Agency,
LA
Oregon Health Sciences 1990—91 67 1.5% NA NA
University, OR
Washington Hospital 1991 66 16.7% 8.3% 4.2%
Center, D.C.
Total 3078 5.1% 4.2% 2.4%
a Tested by ELISA1 at participating OPOs, one donor was common to
two OPOs
bExtrapolated to the donor population
initiation of the study. (2) To determine the sensitivity and
specificity of newer anti-HCV tests for detection of HCV infec-
tion, sera from ELISA1 positive and ELISA1 negative donors
were tested with other currently available assays. Because of the
limited volume of sera available from some donors, not all sera
were tested by all assays. (3) To confirm the effect of viremia on
the risk of transmission, we compared the prevalence of post-
transplantation liver disease and markers of HCV infection
among recipients of organs from anti-HCV positive donors with
and without serum HCV RNA. In this analysis, donors were
classified by a second generation ELISA (ELISA2) because it is
the current screening test for HCV infection. (4) To determine
the risk factors for anti-HCV among cadaver organ donors, we
compared the clinical and laboratory characteristics of anti-HCV
positive and anti-HCV negative donors. In this analysis, donors
were classified by ELISA1 because it was the screening test used
to select them. (5) To determine whether clinical and laboratory
tests could differentiate between anti-HCV positive donors with
and without current HCV infection, we compared these parame-
ters in anti-HCV positive donors with and without HCV RNA.
This analysis was restricted to ELISA2 positive donors. (6) To
assess the performance of screening and confirmatory tests, we
calculated the predictive values of testing strategies to detect
HCV infection. A high negative predictive value (NPV) maintains
a low rate of transmission of HCV infection by infectious donors,
while a high positive predictive value (PPV) reduces wastage of
organs from non-infectious donors.
Study population
Selected organ procurement organizations (OPO) with facili-
ties for retrieval of archived and prospectively collected sera from
organ donors were invited to participate in this study (Table 1).
Cadaver organ donors. Prospectively collected or stored sera
(—70°C) from 3078 cadaver organ donors over a seven year period
(1986—92) were tested for anti-HCV at the individual OPUs by
ELISA1. One hundred and fifty-seven donor sera (5.1%) tested
positive and were included in the study. Organ bank records and
sera were available in 149 and 137 of the ELISA1 positive donors,
respectively. One hundred randomly-selected anti-HCV negative
cadaver organ donors served as controls. The number of anti-
HCV negative controls from each OPO included in the study was
proportional to the number of anti-HCV negative donors at each
OPO. Within each OPO, the anti-HCV negative controls were
randomly selected. Organ bank records and sera were available in
94 and 92 of the anti-HCV negative controls, respectively. All
anti-HCV positive donors and anti-HCV negative controls were
also tested for HCV RNA by PCR and for anti-HCV by ELISA2,
and if sufficient sera were available, by a second generation
recombinant immunoblot assay (RIBA2).
Recipients of organs from anti-HCV positive donors. In three
OPOs (New England Organ Bank, Midwest Organ Bank and
Lifelink Foundation Inc.), follow-up was available on 70 recipients
of organs from 42 anti-HCV (ELISA2) positive donors in whom
sera were available for testing for HCV RNA. In association with
their treating physicians, pre-transplantation and post-transplan-
tation records were reviewed (by BJGP, CFB or CEW, respec-
tively). In surviving recipients, tests for HCV infection were
performed on serum samples obtained at the most recent fol-
low-up visit. In patients who had died and in whom stored sera
were available, a test for anti-HCV was performed on the most
recent sample prior to death. Results on some of these recipients
have been previously reported [4—6].
Definitions
Liver disease is defined as an increase in serum levels of alanine
aminotransferase (ALT) to more than 2.5 times the upper limit of
normal (Normal <40 U/liter) [15]. Acute liver disease is defined
as an elevation in the serum ALT on two or more occasions at
least two weeks apart but for less than six months. Chronic liver
disease was defined as a persistent elevation of ALT for more than
six months [15]. Sub-fulminant liver failure is defined as onset of
hepatic encephalopathy between two weeks and three months
after the onset of jaundice [16].
Laboratory tests
Donor sera were tested for anti-HCV by ELISA1 at the OPOs.
Samples were tested for anti-HCV by ELISA2 at the State
Laboratory Institute, Jamaica Plain, Massachusetts, USA and by
RIBA2 at the Diagnostics Development Department, Chiron
Corporation, Emeryville, Ca. The first generation enzyme-linked
immunosorbent assay, ELISA1 (Ortho Diagnostic Systems, Rari-
tan, New Jersey or Abbot Laboratories, Abbot Park, Illinois,
USA) detects antibody to a recombinant HCV antigen (clOO)
from the non-structural region of the HCV genome. The second
generation enzyme-linked immunosorbent assay, ELISA2 (Ortho
Diagnostic Systems, Raritan, New Jersey, USA) detects antibody
to recombinant HCV antigens derived from three regions (clOO,
c200 and c22) from the non-structural and core regions of the
HCV genome. Both assays were performed according to manu-
facturer's instructions. The second generation recombinant im-
munoblot assay, RIBA2 (Chiron Corporation, Emeryville, Cali-
fornia, USA), a strip immunoblot assay, detects antibody to four
recombinant HCV antigens (5-1-1, clOO c33, c22) from the
non-structural and core regions of the HCV genome and is
currently recommended as a confirmatory test [17, 18]. However,
both positive and negative sera by the ELISA1 were tested by this
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assay. Tests were carried out according to the manufacturer's
instructions, and classified as positive, negative or indeterminate.
For purposes of analysis, indeterminate tests in this high risk
population were considered positive.
Samples were tested for HCV RNA using the reverse tran-
scriptase polymerase chain reaction (RT-PCR) at the San Fran-
cisco Veterans Administration Medical Center, San Francisco,
California, USA [19, 20]. All PCR positive samples and ten
randomly selected PCR negative samples were retested for HCV
RNA by RT-PCR at a second laboratory (Palo Alto Veterans
Administration Medical Center, Palo Alto, California, USA).
Only samples that tested positive for HCV RNA at both labora-
tories were considered positive. To avoid contamination of sam-
ples, nucleic acid extraction and genomic amplification steps were
performed in separate laboratories [21]. Samples were tested in
duplicate and repeated if discrepant results were obtained. Only
repeatedly positive reactions were considered positive. Serum
samples were coded so that the laboratory personnel could not
distinguish the source, and personnel at each laboratory were
blinded to the results of the other assays to prevent bias.
Calculations and statistics
The Appendix shows the equations for calculation of (1)
prevalence of HCV infection among cadaver donors; (2) sensitiv-
ity, specificity, PPV and NPV of various anti-HCV tests; and (3)
transmission of HCV and waste of donor organs for different
strategies for screening and confirmatory testing. The relationship
between risk factors and test results were assessed by Pearson's
statistic for the test (discrete variables) and the Wilcoxon
two-sample test (continuous variables) using two-sided P values.
Since the data were sampled as in a case-control study, we
measured the effect of a two-level risk factor by the odds ratio and
calculated 95% confidence intervals using the standard asymptotic
formula for the variance of the odds ratio [221. Samples missing
values for a particular risk factor were excluded from analysis of
that factor. Concordance between tests was measured by the
kappa statistic. Contingency table analysis and Wilcoxon tests
were run in SAS/Stat (SAS Institute Inc., Cary, North Carolina,
USA).
Results
Prevalence of anti-HCV and HCV RNA among cadaver
organ donors
Anti-HCV was detected by ELISA1 in 157 (5.1%) of 3078
cadaver organ donors at the eight OPOs (Table 1). The preva-
lence of a positive test for ELISA1 ranged from 1.5% to 16.7% in
different OPOs. Anti-HCV was detected by the ELISA2 in 110 of
134 (82.1%) ELISA1 positive donors and none of 92 (0%)
ELISA1 negative controls. Therefore, the prevalence of ELISA2,
extrapolated to all 3078 cadaver organ donors, was 4.2% with a
range from 2.3% to 8.3% among OPOs. HCV RNA was detected
by PCR in 64 of 137 (46.7%) ELISA1 positive donors and none of
92 (0%) ELISA1 negative controls. Therefore, the prevalence of
HCV RNA, extrapolated to the cadaver organ donor population,
was 2.4% with a range from 0.8% to 4.2% among OPOs.
Recipients of organs from ELISA2 positive donors with and
without HCV R1'JA
Follow-up was available on 70 recipients of organs from 42
ELISA2 positive donors in whom sera were available for testing
Table 2. Prevalence of post-transplantation liver disease, markers of
HCV infection and outcome in recipients of organs from ELISA2
positive donors with and without HCV RNA
Recipients of ELISA2 positive
donors
PCR positive PCR negative
Recipient characteristics N = 47 N = 23 P value
Organ
Kidney 37 21
Heart 7 2 0.33
Liver 3 0
Mean follow-up SD 16 11 24 10 0.11
months
Post-transplant liver disease 22/47 (47%) 5/23 (22%) 0.04
Type
Acute 5/22 (23%) 0/5 (0%)
Chronic 16/22 (73%) 5/5 (100%) 0.42
Sub-fulminant 1/22 (4%) 0/5 (0%)
Cause
Non-A, non-B hepatitis 21/22 (95%) 5/5 (100%)
Other 1/22 (5%) 0/5 (0%) 0.63
Post-transplant
ELISA1 positive 12/33 (36%) 3/12 (25%) 0.47
ELISA2 positive 19/26 (73%) 2/8 (25%) 0.01
RIBA2 positive 16/26 (62%) 2/8 (25%) 0.07
PCR positive 26/26 (100%) 3/7 (43%) <0.001
Deaths 8/47 (17%) 3/23 (13%) 0.64
Graft loss 12/47 (26%) 3/23 (13%) 0.23
for HCV RNA (Table 2). Forty-seven recipients received organs
(37 kidneys, 7 hearts and three livers) from 26 ELISA2 positive
donors who tested positive for HCV RNA. The remaining 23
recipients received organs (21 kidneys and two hearts) from 16
ELISA2 positive donors who tested negative for HCV RNA.
Post-transplantation liver disease was observed in 22 of 47 (47%)
recipients from ELISA2 positive donors with HCV RNA com-
pared to five of 23 (22%) recipients from donors without HCV
RNA (P = 0.04). The post-transplantation prevalence of a
positive ELISA2 and HCV RNA was significantly greater in
recipients of organs from ELISA2 positive donors with HCV
RNA compared to recipients from donors without HCV RNA.
Among recipients of organs from ELISA2 positive donors with
HCV RNA, the post-transplantation prevalence of HCV RNA
was 100% (26 of 26 recipients). These data confirm the impor-
tance of serum HCV in ELISA2 positive donors in predicting
transmission of HCV infection.
Estimated rates of transmission of HCV and donor wastage using
current screening tests
Based on the detection of HCV RNA by PCR, the sensitivity of
both ELISA1 and ELISA2 was 100% (Table 3). The NPV of each
test was also 100%. The specificity of ELISA1 was 97.2% (the
range among OPOs was 87.0% to 98.8%) and the specificity of
ELISA2 was 98.1% (range 95.7 to 99.3%). The PPV of ELISA1
was 46.7% (range 25.0 to 59.3%) and the PPV of ELISA2 was
55.1% (range 33.3 to 80.0%). Based on these estimates, discarding
organs from ELISA2 positive donors would eliminate transmis-
sion of infection, but non-life saving organs (kidney, pancreas)
from 1.88% of donors would be wasted.
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Table 3. Proposed testing for screening and confirming HCV infection




Sensitivity Specificity NPV PPV waste
%
Screening tests
ELISA1 100.0 97.2 100.0 46.7 0.00 2.72
ELISA2 100.0 98.1 100.0 55.1 0.00 1.88
Confirmatory tests
ELISA2 optical ratio 98.3 23.9 91.7 62.0 0.04 1.43
>3.0
RIBA2 positivea 100.0 6.8 100.0 41.4 0.00 1.76
Among ELISA2 positive donors
Comparison of clinical and laboratory characteristics of anti-NC V
(ELISAJ) positive and negative donors
Male gender, history of alcohol abuse, history of drug abuse,
blood alcohol levels greater than 100 mg/dl, presence of drugs in
the blood with potential for abuse, and presence of anti-HBc or
anti-CMV were significant risk factors for anti-HCV (Table 4).
The same characteristics were also risk factors for anti-HCV by
ELISA2 (data not shown). The concordance (Kstatistic) between
ELISA2 and RIBA2 was 96% (N = 148).
Comparison of clinical and laboratory characteristics of anti-NC V
(ELISA2) positive donors with and without serum HCV RNA
Among ELISA2 positive donors, the only risk factor for HCV
RNA was an ELISA2 optical ratio (OR) > 3.0 (Table 5).
However, there was large overlap between OR results in HCV
RNA positive and negative patients (data not shown). A positive
RIBA2 was not a risk factor. These data indicate that risk factors
for HCV infection do not distinguish anti-HCV positive donors
with and without ongoing HCV infection as shown by serum
HCV.
Estimated rates of transmission of HCV and donor wastage with
proposed confirmatory tests
We evaluated the performance of a positive RIBA2 and an
ELISA2 or >3.0 as possible confirmatory tests in organ donors
that test positive by ELISA2 (Table 3, lower panel). Extrapolating
to the entire donor population, using RIBA2 as a confirmatory
test in ELISA2 positive donors would maintain transmission at
zero and reduce wastage to 1.76% of donors. Using the ELISA2
OR > 3.0 as a confirmatory test would permit transmission of
infection from 0.04% of donors and further reduce wastage to
1.43% of donors.
Discussion
The use of PCR, with primers directed to the highly conserved
5' untranslated region of the HCV genome, has provided a highly
sensitive tool for the detection of HCV RNA [23—31]. Indeed,
HCV RNA has been detected in the majority of high-risk
anti-HCV positive individuals, such as blood donors with elevated
serum alanine aminotransferase levels, intravenous drug abusers,
hemophiliacs and patients with non-A, non-B hepatitis [26—30].
Further, HCV RNA is rarely detected in low-risk populations with
a negative anti-HCV test [26]. Therefore, we used the PCR as the
"standard" to denote the presence of persistent "productive viral
infection" [24]. Our results confirm that detection of serum HCV
RNA by PCR in cadaver organ donors indicates a high risk of
transmission of HCV infection: 100% of recipients tested positive
for HCV RNA after transplantation and 47% of recipients
developed post-transplantation liver disease. Therefore, it is es-
sential to test organ donors for HCV infection.
We observed a 2.4% prevalence of serum HCV RNA among
cadaver donors, with a range from 0.8% to 4.2% among the eight
OPOs that participated in this study. Because of the low preva-
lence of HCV infection, the PPV of the ELISA1 and ELISA2
anti-HCV tests were only 46,7 and 55.1%, respectively, with a
broad range among OPOs. We suggest that differences in the
prevalence of donor HCV infection and in the PPV of anti-HCV
tests at different OPOs may account for the reported differences
in the prevalence of post-transplantation liver disease and mark-
ers of HCV infection among recipients of organs from anti-HCV
positive donors [4-10]. Further, our data indicate that the pres-
ence of liver disease or a positive test for anti-HCV does not
identify all recipients with HCV infection. Failure to test recipi-
ents for HCV RNA underestimates the prevalence of HCV
infection, and may be another explanation for the differences in
post-transplantation HCV infection observed at different OPOs
[8, 9].
The absence of HCV RNA in a significant proportion of
anti-HCV positive organ donors in this study could be due false
positive tests for anti-HCV, false negative tests for HCV RNA, or
persistent antibody following resolution of infection. The similar-
ity of clinical features among ELISA2 positive donors with and
without HCV RNA suggests that the ELISA2 positive donors
without HCV RNA were not likely to be false positive. Rather, it
is more likely that they had indeed been exposed to HCV and
either cleared the virus or had low levels of viremia that could not
be detected by PCR. The cadaver donor sera tested in this study
were stored for as long as seven years, and it is possible that
prolonged storage and frequent freeze-thaw cycles may have
resulted in a degradation of HCV RNA. Indeed, Busch et a! have
shown that imperfect handling and/or storage of blood samples
can lead to failure to detect HCV RNA in almost 40% of samples
[24]. These authors suggested that the low rate of detection of
HCV RNA in anti-HCV positive blood donors in some studies
[13, 26, 31] could reflect false negatives due to poor handling and
storage of test samples. We too observed five patients with
post-transplantation liver disease who received organs from
ELISA2 positive donors without HCV RNA. However, of these
five patients, the single patient in whom pre-transplantation
serum was available for testing had pre-transplantation HCV
infection. Moreover, the significant differences in the prevalence
of post-transplantation liver disease and HCV RNA among
recipients of organs from ELISA2 positive donors with and
without HCV RNA suggest that most of the HCV RNA negative
donors were truly negative.
None of the anti-HCV negative organ donors in this study
tested positive for HCV RNA (sensitivity was 100%). Conse-
quently, the NPV was 100%, and transmission of HCV infection
by anti-HCV negative donors would be extremely unlikely. There-
fore, using the ELISA2 anti-HCV test to screen organ donors
could virtually eliminate transmission of HCV infection. The
specificity of the anti-HCV tests was also high. However, because
of the low prevalence of infection, the PPV of ELISA2 was only
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Table 4. Clinical and laboratory characteristics of ELISA1 positive and negative donors
ELISA1 positive ELISA1 negative
Median (range) Median (range) 95% Confidence
Clinical and laboratory characteristics N or percent N or percent Odds ratioa interval&' P valuec
Ageyears 148 32 (10—61) 93 31(1—65) 0.67
Gender % male 147 77.6% 93 60.2% 2.28 1.29—4.03 0.004
Race % Caucasian 147 81.6% 91 90.1% 0.49 0.22—1.09 0.08
Causes of death % unnatural 144 67.4% 87 59.8% 1.39 0.80—2.41 0.24
History of alcohol abuse % yes 63 76,2% 25 44.0% 4.07 1.53—10.85 0.004
History of drug abuse % yes 61 70.5% 20 20.0% 9.56 2.80—32.56 <0.001
Blood product transfusions number 130 2 (0—65) 84 2 (0—50) 0.92
Blood product transfusions % yes 130 63.9% 84 63.1% 1.03 0.58—1.83 0.91
Alanine aminotransferase levels U/liter 99 41(8—476) 60 30 (3—445) 0.10
Alanine aminotransferase levels % 99 29.3% 60 21,7% 1.50 0.71—3.18 0.29
>100 U/liter
Blood alcohol level mg/dl 41 100 (0—3300) 27 0 (0—404) 0.004
Blood alcohol levels % >100 mg/dl 41 56.1% 27 25.9% 3.65 1.27—10.53
Positive toxic screen % positive" 21 47.6% 22 0% Infinite
0.01
<0.001
Anti-HBs % positive 32 31.3% 12 8.3% 5.00 0.57—44.20 0.12
Anti-HBc %positive 58 29.3% 81 2.5% 16.38 3.61—74.36 <0.001
Anti-CMV %positive 136 64.7% 79 46.8% 2.08 1.18—3.66 0.01
Odds ratio of being ELISA1 positive in donors with the characteristic
b 95% Confidence intervals of the odds ratio
Wilcoxon for continuous variables and Chi-square for discrete variables
d Presence of drugs with potential for abuse
Table 5. Clinical and laboratory characteristics of ELISA2 positive donors with and without HCV RNA in the serum
PCR positive PCR negative
Median (range) Median (range) 95% Confidence
Clinical and laboratory characteristics N or percent N or percent Odds ratioa intervalst' P valuec
Age years 60 32 (18—55) 49 30 (10—57) 0.20
Gender % male 60 83.3% 48 75.0% 1.67 0.65—4.28 0.29
Race % Caucasian 60 85.0% 49 79.6% 1.45 0.54—3.92 0.46
Causes of death % unnatural 59 72.9% 47 68.1% 1.26 0.54—2.92 0.59
History of alcohol abuse % yes 31 90.3% 13 84.6% 1.70 0.25—11.58 0.59
History of drug abuse % yes 28 85.7% 14 71.4% 2.40 0.50—11.54 0.27
Blood product transfusions number 53 2 (0—65) 43 2 (0—20) 0.86
Blood product transfusions % yes 53 62.3% 43 65.1% 0.88 0.38—2.04 0.77
Alanine aminotransferase levels U/liter 40 41(9—327) 30 46 (8—476) 0.38
Alanine aminotransferase levels % >100 U/liter 40 32.5% 30 26.7% 1.32 0.47—3.77 0.60
Blood alcohol level mg/dl 19 258 (0—438) 12 139 (0—3300) 0.68
Blood alcohol levels % >100 mg/dl 19 68.4% 12 58.3% 155 0.35—6.94
Positive toxic screen %positivë' 9 66.7% 5 60.0% 1.33 0.14—12.82
0.57
0.80
Anti-HBs %positive 17 35.3% 10 30.0% 1.27 0.24—6.82 0.78
Anti-HBc %positive 23 43.5% 16 31.3% 1.69 0.44—6.47 0.44
Anti-CMV %positive 55 58.2% 44 63.6% 0.80 0.35—1.80 0.58
ELISA2 optical ratio >3.0 58 98.3% 46 76.1% 17.91 2.22—144.83 <0.001
RIBA2 % positive 29 100% 44 93.2% Infinite 0.15
a Odds ratio of being PCR positive in ELISA2 positive donors with the characteristic
'95% Confidence intervals of the odds ratio
Wilcoxon for continuous variables and Chi-square for discrete variables
d Presence of drugs with potential for abuse
55.1%. Using the ELISA2 anti-HCV test to screen organ donors
would lead to wastage of organs from 44.9% of donors with a
positive test. Given the prevalence of HCV infection, a morato-
rium on the use of non-life saving transplants from ELISA2
positive organ donors would lead to waste of organs from 1.88%
of donors. One strategy to minimize wastage is to identify clinical
or laboratory characteristics that differentiate anti-HCV positive
donors with and without HCV RNA.
We observed differences in clinical and laboratory characteris-
tics of anti-HCV positive cadaver donors and anti-HCV negative
controls that are consistent with known epidemiologic features of
populations exposed to parenterally transmitted viruses. How-
ever, these differences did not distinguish anti-HCV positive
donors with and without serum HCV RNA. Some investigators
have suggested that anti-HCV positive donors without history of
drug abuse or homosexual lifestyle, absence of anti-HBs or
anti-HBc, and normal serum alanine aminotransferase levels are
at low risk of transmitting disease and could hence be used for
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transplantation [9]. However, our results suggest that there are no
"low-risk" anti-HCV positive cadaver organ donors.
Another strategy to minimize wastage is to develop a confirma-
toly test for use in donors with a positive screening test. The
RIBA2 has been suggested as a confirmatory test in blood donors
[20, 21,32]. However, our results in cadaver organ donors indicate
that it is not specific enough to distinguish ELISA2 positive
donors with and without serum HCV RNA, and would not
appreciably reduce organ wastage. Hence, newer confirmatory
tests with an even greater specificity need to be developed in order
to reduce organ waste.
Finally, even if a strategy is identified that would differentiate
anti-HCV positive donors with and without HCV RNA, the fact
remains that 2.4% of cadaver organ donors test positive for serum
HCV RNA by PCR, and would not be suitable for transplantation
of non-life saving organs. Recently, it has been suggested that
organs from HCV RNA positive donors could be safely trans-
planted into HCV RNA positive recipients [33]. Long-term trials
are necessary to evaluate the risk of post-transplantation liver
disease in these recipients. If the safety of this practice is
established, organs from donors with anti-HCV could be reserved
for recipients with serum HCV RNA. This practice could poten-
tially eliminate both the need for confirmatory testing in donors
with anti-HCV and the wastage of organs from anti-HCV positive
donors.
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Appendix
Since the ELISA1 positive donors in this study represent all the ELISA1
positive donors in the OPOs, but the ELISA1 negative controls represent
only a sample of the ELISA1 negative donors, we used the following
formulas to calculate the prevalence of a positive test for HCV infection
(ELISA1, ELISA2, PCR) in each OPO and in the donor population:
Test prevalence = K/N
K = A*B+ C*D
where "K" is the number of test positive samples, "N" is the population of
the OPO, "A" is the number of ELISA1 positive samples, "B" is the ratio
of the number of test positive samples to the number of ELISA1 positive
samples tested, "C" is the number of ELISA1 negative samples and "D"
is the ratio of the number of test positive samples to the number of
ELISA1 negative samples tested.
We calculated the sensitivity, specificity, PPV and NPV of each test
based on PCR in each OPO and in the donor population as follows:
Sensitivity = a/(a + c)
Specificity = d/(b + d)
PPV = a/(a+ b)
NPV = d/(c + d)
where "a" is the number of test positive and PCR positive samples, "b" is
the number of test positive and PCR negative samples, "c" is the number
of test negative and PCR positive samples, and "d" is the number of test
negative and PCR negative samples. Then "a" is calculated by multiplying
the total number of test positive samples (K) by the ratio of the number of
test positive and PCR positive samples to the number of test positive
samples tested by PCR, and b = K — a. Similarly, "d" is calculated by
multiplying the total number of test negative samples (N — K) by the ratio
of the number of test negative and PCR negative samples to the number
of test negative samples tested by PCR, and c = (N — K) d.
We used the PPV and NPV of various strategies for screening and
confirmatory testing to estimate the proportion of donors that would
transmit HCV and that would be wasted. Estimates of transmission
(transplantation of organs from a donor with serum HCV RNA) and
waste (discard of non-life saving organs, such as kidneys and pancreas,
from donors without serum HCV RNA) were calculated as follows:
Transmission = (1 — NPV)*(1-test prevalence)
Waste = (1 — PPV)*(test prevalence)
For screening strategies, test prevalence was defined as the prevalence of
the test in the donor population. For confirmatory strategies, test preva-
lence was defined as the prevalence of the test among donors with a
positive screening test.
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